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vickystokes22@hotmail.comSummaryOpiate drugs such as morphine are in extensive use for pain relief and palliation. It is well established that these drugs can
cause changes in endocrine function, but such effects are not always sufficiently appreciated in clinical practice, especially in
relation to the hypothalamic–pituitary–adrenal (HPA) axis. Herein, we report on an 18-year-oldmanwhowas diagnosedwith
a slipped left femoral epiphysis following a long history of pain in his leg. On examination, he was thought to look relatively
young for his age and therefore the orthopaedic surgeons arranged an endocrine assessment, which showed an
undetectable concentration of serum cortisol and a suppressed concentration of testosterone; therefore, he was referred
urgently with a diagnosis of hypopituitarism. We elicited a history that he had been treated with opiate analgesics for 3 days
at the time of his original blood tests. Full endocrine assessment including a short Synacthen test revealed that he now had
normal adrenal and pituitary function. We conclude that his morphine therapy had caused profound suppression of his HPA
and pituitary–gonadal axes and suggest that clinicians should be aware of these significant changes in patients on even
short-term opiate therapy.Learning points:
† Therapy with opiates is the standard therapy for severe acute and chronic pain.
† Such drugs cause profound changes in endocrine function.
† Importantly, opiates suppress the HPA axis at a central level.
† Short-term therapy with morphine could be the cause of biochemical adrenocortical insufficiency.
† Morphine and related drugs also suppress the pituitary–gonadal axis.
† After discontinuation of therapy with such drugs, adrenal function improves.Background
Opiates are important agents in the treatment of pain and
have also been used for centuries as substances of abuse (1).
They play an important role in the management of chronic
and acute pain in many patients, including those with
cancer in all age groups (2). Opiate-induced effects in the
endocrine system are commonand havebeen recognised for
more than a century, but are still poorly understood; these
effects represent one of the several described side-effects and
possible toxicities associated with the chronic use of
opiates (3). Although their effects on gonadal function arewell recognised, herein, we present a case of profound
adrenal failure after short-term therapy with morphine.Case presentation
An 18-year-old man with a suspected diagnosis of hypopi-
tuitarism was referred by the orthopaedic team. He had
initially presented to the Emergency Department with
acute-on-chronic pain in his leg following a fall from his
bicycle. He had taken codeine 30 mg four times daily for
1 day before presenting to the hospital. He was given 30 mghttp://www.edmcasereports.com
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15 mg oral morphine at 1555 h that day. He was diagnosed
with a slipped upper femoral epiphysis and operated on by
the orthopaedic team. On the day of his operation, he was
given 3 mg i.v. morphine immediately post-operatively and
then 60 mg oral morphine and 100 mg tramadol in divided
doses throughout the day. On the following day, he
continued to experience pain and was given 50 mg oral
morphine and 100 mg tramadol throughout the day. On
day 3 post-operatively, suspicions were raised as he appeared
young for his age and was relatively old to present with a
slipped upper femoral epiphysis. His basal pituitary function
was assessed and found to be abnormal. He was started on
hydrocortisone therapy and discharged home with a small
supply of tramadol 100 mg on an ‘as-required’ basis, with
endocrine follow-up being arranged. Endocrine follow-up
took place 1 month later. On examination at endocrine
follow-up, he looked healthy and had good muscular
development, but appeared to be a little young for his age,
had rather sparse body hair, well-developed pubic and
genital hair, and a normal penis and testicles, which were
bilaterally 15 ml. He reported a gradual increase in body
bulk and hair, regular morning erections and occasional
shaving; his voice changed about the same age as his peers,
and he had normal eyesight and no headaches. He did not
have any other significant past medical, family or social
history, and the rest of the examination was unremarkable.Investigation
The orthopaedic surgeons found extremely low concen-
trations of cortisol and testosterone (no inhalers or creams).
His serum cortisol concentration was 15 nmol/l (normal
range: 180–620), testosterone concentration !0.4 nmol/l
(normal range: 8.4–28.7), luteinizing hormone (LH)
concentration 1.1 IU/l (normal range: 1.5–9.3), follicle-
stimulating hormone (FSH) concentration 2.2 IU/l (normal
range: 2.0–20), thyroid-stimulating hormone (TSH) concen-
tration 0.56 mU/l (normal range: 0.35–5.5), free thyroxine
concentration 13.7 pmol/l (normal range: 11–19.5), free
tri-iodothyronine concentration 2.7 pmol/l (normal range:
3.5–6.5), insulin-like growth factor 1 concentration
48.2 nmol/l (normal range: 13.6–64.1), and prolactin
concentration 169 mU/l (normal range: 45–375). He was
started on 10 mg hydrocortisone in the morning, 5 mg at
lunchtime and 5 mg in the evening. After 3 months, he was
readmitted for further treatment of his hip. He had
discontinued taking opiate analgesics at least 2 months
earlier and was taking only hydrocortisone and paraceta-
mol. Pituitary function was re-checked before he took hishttp://www.edmcasereports.commorning dose of hydrocortisone. He underwent a short
Synacthen test: this revealed a baseline cortisol concen-
tration of 293 nmol/l, which increased to 589 nmol/l at
30 min and to 702 nmol/l at 60 min. His testosterone
concentration was 12.2 nmol/l, LH concentration 4.1 IU/l,
FSH concentration 4.4 IU/l, and TSH concentration
2.54 mIU/l. He had a pituitary magnetic resonance imaging
scan that revealed a normal pituitary gland.Treatment
Hydrocortisone treatment was discontinued and analge-
sics were no longer required.Outcome and follow-up
He was reassured that he was not hypopituitary, and he
remains well in the absence of replacement therapy.Discussion
Our case report suggests that short-term therapy with
morphine may mimic adrenocortical failure. It is known
that opioids and opiates inhibit the hypothalamic–pituitary–
adrenal (HPA) axis at multiple levels. The reduced concen-
trations of CRH and vasopressin reduce the secretion of
adrenocorticotropic hormone (ACTH) from the pituitary and
the capacity of the pituitary to respond to stimulation and
directly interfere with adrenal gland production of cortisol
and DHEA independently or by CNS down-regulation.
Evidence in the literature also suggests that opiates may
interfere with the release of adrenal androgens such as
DHEAS(3).AccordingtoTsagarakis etal. (4), thepredominant
effect of morphine on hypothalamic CRH-41 release in vitro is
the suppression of the release induced by a variety of putative
neurotransmitters and depolarising agents. Opioid-induced
inhibition of the HPA axis is mediated by different
mechanisms at the hypothalamic level, with evidence being
in favour of d- and k-opiate receptor involvement in the
control of ACTH release (5), and Delitala et al. (6) observed a
drop in serum cortisol concentrations following therapy with
morphine and other opiates in humans. Recently, Debono
et al. (7) have reported a case of a 21-year-old female with
tramadone-induced adrenal insufficiency. Another case
report has described a patient with back pain on fentanyl
application who presented adrenocortical insufficiency (8).
A similar observation has been made in a patient on
hydromorphone therapy (9).
We conclude that the use of potent opiate analgesics,
even in the short term, may profoundly suppress the HPA2
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rapidly reverse on cessation of therapy. Clinicians need to
be aware of these potent effects if they are to avoid the
fallacious diagnosis of hypopituitarism.Declaration of interest
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